KPV for gut inflammation: from α-MSH fragment to colitis models

What KPV is

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid hormone best known for skin pigmentation, but it also damps inflammation. In the 1980s, researchers found that its last three amino acids, lysine, proline and valine, carried some of that anti-inflammatory activity on their own. In rabbits made feverish, the tripeptide reduced fever whether given into the brain or a vein, though less potently than alpha-MSH, and the authors concluded it was not simply a weaker copy of the parent hormone ¹.

That tripeptide is KPV Low. It is the shortest peptide in the current wave of research peptides, and that shortness is part of its appeal to sellers, who market it in capsules, creams and injections for gut inflammation, 'leaky gut' and skin conditions. Our alpha-MSH entry covers the parent hormone and the approved drugs built on it.

How it seems to work

KPV does not appear to work the way alpha-MSH does. In mice with crystal-induced peritonitis, KPV reduced the build-up of neutrophils as alpha-MSH did, but unlike alpha-MSH it did not raise cAMP or inhibit cytokine release from macrophages, a melanocortin receptor blocker did not stop it, and it still worked in mice lacking a functional MC1 receptor ². In skin cells, neither KPV nor alpha-MSH raised cAMP, and KPV's effects depended on the experimental conditions ³.

The clearest mechanism came from the gut. In 2008, researchers showed that nanomolar KPV blocked NF-kappaB and MAP kinase signalling, two central inflammatory pathways, in human intestinal epithelial cells and T cells, reducing inflammatory cytokines, and that it entered cells through PepT1, a transporter for small peptides that rises in inflamed gut tissue ⁴. In airway cells, KPV entered the nucleus and inhibited NF-kappaB and inflammatory chemokines ⁵. A peptide that slips into inflamed cells and turns down NF-kappaB is an appealing idea for inflammatory bowel disease. It is still an idea.

The colitis studies

The same 2008 study gave KPV in drinking water to mice with two chemically induced forms of colitis, and it reduced the severity of inflammation ⁴. A second group found that KPV-treated mice with DSS colitis recovered earlier and regained more weight, with fewer inflammatory cells and lower myeloperoxidase activity, a marker of neutrophil activity, and that KPV also led to recovery in a T-cell transfer model of colitis, which more closely resembles immune-driven disease ⁶.

Those are encouraging results, and they come from two independent groups. But mouse colitis models are induced by chemicals or by transferring immune cells into mice without their own, over days or weeks. Many treatments that work in these models have failed in people with ulcerative colitis or Crohn's disease, which are chronic, relapsing conditions driven by genetics, the microbiome and the immune system over years. Our guide to reading a study explains why the animal rung of the evidence ladder is so often where promising compounds stop.

A complication: PepT1 and tumours

The transporter that lets KPV into inflamed cells has its own story. In a 2016 study, mice engineered to make human PepT1 in the gut developed more and larger tumours in a model of colitis-associated cancer, mice lacking PepT1 developed fewer, and biopsies of human colorectal cancers showed raised PepT1. KPV prevented tumour formation in normal mice, but its effects depended on PepT1 ⁷. What that means for people is unknown. It is a reminder that the pathways a gut peptide uses are involved in more than inflammation.

The delivery research

A three-amino-acid peptide is fragile. A 2015 laboratory study that developed a test for measuring KPV found that under acid, alkali and oxidising stress it broke down mainly into a cyclic dipeptide, a diketopiperazine ⁸, which matters for how long a dissolved product stays what its label says. Applied to human skin in the laboratory, KPV did not cross by passive diffusion at detectable levels; microneedles and electrical delivery increased it ⁹.

For the gut, researchers have built delivery systems. KPV loaded into hyaluronic-acid-coated nanoparticles, given by mouth in a chitosan-alginate hydrogel, reached colonic cells and protected the gut lining in mice with colitis ¹⁰. Held in a polyglutamic-acid hydrogel and given rectally, it kept its activity and improved colitis in mice ¹¹. A charged double-network hydrogel that stuck to inflamed colon lining in rats held KPV in place and improved colitis more than KPV alone ¹². These are serious engineering efforts, and they share a conclusion: plain KPV, swallowed or dissolved, is not an efficient way to get it where it is meant to act.

Beyond the gut: skin and fat studies

Recent KPV research has widened. In human skin cells damaged by fine particulate air pollution, KPV restored cell survival, cut the inflammatory signal IL-1 beta and reduced inflammatory cell death in a three-dimensional skin model ¹³. In a 2026 study, KPV reduced fat accumulation in cultured fat-cell precursors, and mice on a high-fat diet given KPV by mouth gained less weight, with less fat tissue, smaller livers and lower cholesterol ¹⁴. Both are early laboratory and mouse findings. They will likely be cited in marketing for skin and weight loss, and they carry the same limitation as everything else on this page: no person has taken part.

What about 'leaky gut'?

Much KPV marketing targets 'leaky gut', a term used loosely online for symptoms attributed to a more permeable gut lining. Intestinal permeability is a real, measurable property and is increased in conditions such as inflammatory bowel disease and coeliac disease, but 'leaky gut' as a stand-alone diagnosis for vague symptoms is not well defined. Even if KPV tightened the gut barrier in mice, that would not show it helps people with symptoms sold under that label. Anyone with persistent gut symptoms should be assessed, because coeliac disease, inflammatory bowel disease and other treatable conditions can look alike early on.

The research at a glance

What FDA said, and what its committee did

KPV came before FDA's Pharmacy Compounding Advisory Committee on July 23, 2026, as two substances, the free base and the acetate salt. The nomination had been withdrawn, and FDA evaluated it at its own discretion ¹⁵. Notably, it was nominated for wound healing and inflammatory skin conditions such as psoriasis and eczema, by topical and oral routes, not for gut disease ¹⁵.

FDA's briefing was blunt. Its reviewers could not locate information on the use of KPV in humans at all, so no conclusion on clinical safety or effectiveness was possible; they said neither form was well characterised, with no substance-specific quality control data in the literature and no certificate of analysis in the nomination; and they said potential safety risks in people, including immunogenicity, were unknown, not absent. FDA proposed not adding either form to the list ¹⁵. The committee voted 8 to 6, with one abstention, to recommend it anyway ¹⁵. As of October 3, 2026, FDA had not acted on that vote, so KPV could not be lawfully compounded. Our July 2026 PCAC page sets out every vote.

What is being sold

KPV is sold online as capsules, creams and injectable powders, labelled for research use only, with claims about gut healing, 'leaky gut' and skin. None of those claims rests on a human study. The products' contents are unverified, and FDA's point about characterisation applies directly: with no agreed quality standard, there is no reference against which a buyer can judge a product. KPV also appears in some multi-peptide blends; our TB-500, BPC-157 and KPV blend page sets out what that combination contains.

For people with inflammatory bowel disease

Ulcerative colitis and Crohn's disease have many approved treatments tested in large trials, and the field continues to add new ones. KPV is not among them, and replacing or delaying effective treatment risks flares, complications and surgery. If you are interested in KPV, raise it with your gastroenterologist, and tell them about anything you are already taking. Our comparison of KPV and BPC-157, the two peptides most often sold for the gut, sets out how little human evidence either has.

For athletes

KPV is not named on WADA's Prohibited List, but as a substance with no current approval for human therapeutic use it falls under the S0 catch-all for non-approved substances, which is prohibited at all times ¹⁶.

The bottom line

As of October 3, 2026, KPV is a well-studied laboratory peptide with a plausible mechanism and positive results in mouse colitis, from more than one group, and an inventive delivery literature. It has never been given to a person in a published study, FDA's reviewers could find no human use, and its quality is uncharacterised. A favourable committee vote, for skin and wound uses, has not changed any of that.

Frequently asked questions

What is KPV peptide?

KPV is lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone. In cell and animal studies it reduced inflammation, partly by blocking NF-kappaB.

Does KPV help colitis?

It reduced colitis in several mouse models. No published study has tested it in people with ulcerative colitis, Crohn's disease or any other condition.

Is KPV FDA-approved or legal to compound?

It is not approved. FDA's advisory committee voted 8 to 6 in July 2026 to recommend it for compounding, but FDA had not acted as of October 3, 2026, so pharmacies could not lawfully compound it.

Is KPV safe?

Unknown. FDA said information on human use was non-existent and that safety risks, including immune reactions, could not be assessed. It has not been studied in people.

Related on Grey Peptides

• KPV
• Alpha-MSH
• KPV vs BPC-157

Sources

1. Richards, D. B., et al. (1984). Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides, 5(4), 815-7. PMID: 6333677
2. Getting, S. J., et al. (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther, 306(2), 631-7. PMID: 12750433
3. Elliott, R. J., et al. (2004). alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol, 122(4), 1010-9. PMID: 15102092
4. Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166-78. PMID: 18061177
5. Land, S. C. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol, 4(2), 59-73. PMID: 22837805
6. Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 14(3), 324-31. PMID: 18092346
7. Viennois, E., et al. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol, 2(3), 340-357. PMID: 27458604
8. Pawar, K. R., et al. (2015). Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates. Biomed Chromatogr, 29(5), 716-21. PMID: 25298219
9. Pawar, K., et al. (2017). Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. J Pharm Sci, 106(7), 1814-1820. PMID: 28343991
10. Xiao, B., et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther, 25(7), 1628-1640. PMID: 28143741
11. Sun, J., et al. (2021). Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomater Sci Eng, 7(10), 4859-4869. PMID: 34547895
12. Zhao, Y., et al. (2022). A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater, 143, 233-252. PMID: 35245681
13. Sung, J., et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell, 95, 102837. PMID: 40073467
14. An, S. H., et al. (2026). KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. Tissue Cell, 104(Pt 1), 103837. PMID: 42585803
15. U.S. Food and Drug Administration. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: briefing document and votes for KPV (free base) and KPV acetate (8 yes, 6 no, 1 abstain). Page last updated August 6, 2026; re-read October 3, 2026. FDA
16. World Anti-Doping Agency. The 2026 Prohibited List, S0 Non-approved substances; the 2027 List keeps the same section. Read in full July 16, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.